doi: 10.1016/S1474-4422(22)00529-4.
Lecanemab slows Alzheimer's disease: hope and challenges
Affiliations
- PMID: 36681438
- DOI: 10.1016/S1474-4422(22)00529-4
Item in Clipboard
Lecanemab slows Alzheimer's disease: hope and challenges
Lancet Neurol.
2023 Feb.
No abstract available
Conflict of interest statement
NF reports consultancy services for Biogen, Eli Lilly, Ionis, and Roche (all payments to University College London) and has participated on a data safety monitoring board for Biogen. SM declares no competing interests.
Similar articles
-
Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231209839. doi: 10.1177/03946320231209839. Int J Immunopathol Pharmacol. 2023. PMID: 37902139 Free PMC article.
-
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8. Alzheimers Res Ther. 2021. PMID: 33865446 Free PMC article. Clinical Trial.
-
Profiling lecanemab as a treatment option for Alzheimer's disease.Expert Rev Neurother. 2024 May;24(5):433-441. doi: 10.1080/14737175.2024.2333970. Epub 2024 Apr 3. Expert Rev Neurother. 2024. PMID: 38566584 Review.
-
[Disease-modifying Drugs in Alzheimer's Disease: Indications and Efficacy Evaluation].Brain Nerve. 2024 Sep;76(9):1005-1009. doi: 10.11477/mf.1416202725. Brain Nerve. 2024. PMID: 39251219 Japanese.
-
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379. Adv Clin Exp Med. 2023. PMID: 37676096
Cited by
-
Research Progress in the Molecular Mechanism of NLRP3 Inflammasome in Alzheimer's Disease and Regulation by Natural Plant Products.Mol Neurobiol. 2025 Jun;62(6):7296-7312. doi: 10.1007/s12035-025-04715-w. Epub 2025 Jan 28. Mol Neurobiol. 2025. PMID: 39875780 Review.
-
Recent progress of nanomedicine in the treatment of Alzheimer's disease.Front Cell Dev Biol. 2023 Jun 29;11:1228679. doi: 10.3389/fcell.2023.1228679. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37457297 Free PMC article. Review.
-
Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.Neurol Ther. 2023 Dec;12(6):1883-1907. doi: 10.1007/s40120-023-00541-1. Epub 2023 Oct 9. Neurol Ther. 2023. PMID: 37812325 Free PMC article. Review.
-
Deep Learning-Driven Exploration of Pyrroloquinoline Quinone Neuroprotective Activity in Alzheimer's Disease.Adv Sci (Weinh). 2024 May;11(18):e2308970. doi: 10.1002/advs.202308970. Epub 2024 Mar 7. Adv Sci (Weinh). 2024. PMID: 38454653 Free PMC article.
-
The appropriate sample-handling procedure for measuring the plasma β-amyloid level using a fully automated immunoassay.Sci Rep. 2024 Jun 20;14(1):14266. doi: 10.1038/s41598-024-65264-1. Sci Rep. 2024. PMID: 38902510 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
